Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.15 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.15 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management did not express strong optimism or concern during the call. They emphasized the importance of their ongoing research efforts.
Management did not provide specific guidance for future quarters.
The call focused on ongoing projects and research developments.
Protagonist Therapeutics reported a loss per share of $0.15, which did not meet any consensus expectations as revenue figures were not disclosed. Despite this, the stock rose by 1.16%, likely reflecting investor confidence in the company's ongoing research initiatives and future potential. The lack of guidance may lead to uncertainty among investors moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DAVE INC A
Mar 5, 2018